New update strongly recommends against use of sotrovimab and casirivimab-imdevimab for patients with COVID-19<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
FRIDAY, Sept. 16, 2022 (HealthDay News) — In the living guideline developed by the World Health Organization and published in The BMJ<\/em>, recommendations on drug options for the treatment of COVID-19 have been updated.<\/p>\n Arnav Agarwa, M.D., from McMaster University in Hamilton, Ontario, Canada, and colleagues produced the 12th version of the living guideline discussing the role of drugs in the treatment of COVID-19. New evidence was reviewed to update the earlier versions of these guidelines.<\/p>\n The authors updated recommendations for remdesivir, conditionally recommending its use in patients with severe COVID-19 and conditionally recommending against its use in critical COVID-19. The benefits of remdesivir are considered to be modest and of moderate certainty for key outcomes. Use of interleukin-6 receptor blockers (tocilizumab or sarilumab) may be combined with the Janus kinase inhibitor baricitinib, in addition to corticosteroids, for severe or critical COVID-19. Strong recommendations are provided against the use of sotrovimab and casirivimab-imdevimab for patients with nonsevere COVID-19, replacing the previous conditional recommendations for their use. There is a need for clinical trial evidence to confirm the clinical efficacy of new monoclonal antibodies that reliably neutralize circulating severe acute respiratory syndrome coronavirus 2 strains in vitro.<\/p>\n “Existing and emerging evidence demonstrates remaining uncertainties concerning treatment effects for all outcomes of importance to patients,” the authors write. “There is also a need for better evidence on values and preferences of patients with COVID-19.”<\/p>\n Abstract\/Full Text<\/a><\/p>\n <\/p>\n <\/p>\n <\/p>\n <\/p>\n <\/p>\n <\/p>\n <\/p>\n <\/i><\/p>\n